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Summary
Macrophages respond to their microenvironment and develop polarized
functions critical for orchestrating appropriate inflammatory responses.
Classical (M1) activation eliminates pathogens while alternative (M2) acti-
vation promotes regulation and repair. M1 macrophage activation is
strongly associated with suppressor of cytokine signalling 3 (SOCS3)
expression in vitro, but the functional consequences of this are unclear
and the role of SOCS3 in M1-macrophage polarization in vivo remains
controversial. To address these questions, we defined the characteristics
and function of SOCS3-expressing macrophages in vivo and identified
potential mechanisms of SOCS3 action. Macrophages infiltrating inflamed
glomeruli in a model of acute nephritis show significant up-regulation of
SOCS3 that co-localizes with the M1-activation marker, inducible nitric
oxide synthase. Numbers of SOCS3hi-expressing, but not SOCS1hi-express-
ing, macrophages correlate strongly with the severity of renal injury, sup-
porting their inflammatory role in vivo. Adoptive transfer of SOCS3-short
interfering RNA-silenced macrophages into a peritonitis model demon-
strated the importance of SOCS3 in driving production of pro-inflamma-
tory IL-6 and nitric oxide, while curtailing expression of anti-inflammatory
IL-10 and SOCS1. SOCS3-induced pro-inflammatory effects were due, at
least in part, to its role in controlling activation and nuclear accumulation
of nuclear factor-jB and activity of phosphatidylinositol 3-kinase. We show
for the first time that SOCS3 also directs the functions of human mono-
cyte-derived macrophages, including efficient M1-induced cytokine
production (IL-1b, IL-6, IL-23, IL-12), attenuated signal transducer and
activator of transcription 3 activity and ability of antigen-loaded macro-
phages to drive T-cell responses. Hence, M1-associated SOCS3 was a posi-
tive regulator of pro-inflammatory responses in our rodent models and
up-regulated SOCS3 is essential for effective M1-macrophage activation
and function in human macrophages.
Keywords: glomerulonephritis; inflammation; M1 macrophage; nuclear
factor-jB; suppressor of cytokine signalling 3.
Introduction
Macrophages are key cellular components of innate
immunity. They detect and respond to pathogenic and
tissue-derived signals to clear pathogens, remodel injured
tissue and restore tissue homeostasis.1 Their diverse but
polarized functional phenotypes, driven by micro-envi-
ronmental cues, allow them to adapt readily to changing
conditions within tissues.2 The extent of macrophage het-
erogeneity and the polarizing stimuli that exist in vivo are
far from clear but two main functional phenotypes have
been well described experimentally.3,4 Classical or M1
Abbreviations: BMDM, bone-marrow-derived macrophages; iNOS, inducible nitric oxide synthase; NTN, nephrotoxic nephritis;
PI3K, phosphatidylinositol-3-kinase; siRNA, short-interfering RNA; SOCS, suppressor of cytokine signalling
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activated macrophages, induced by microbial products in
the presence or absence of interferon-c (IFN-c) are micro-
bicidal, tumoricidal and pro-inflammatory. Alternative or
M2 activation by IL-4 or IL-13 gives rise to anti-inflam-
matory tissue-remodelling cells, while immunoregulatory
or M2-like macrophages up-regulate IL-10 to dampen
immune responses. As many pathologies such as chronic
inflammation, fibrosis and cancer are driven by dysregu-
lated macrophage function,1,3,5 there is growing interest in
how macrophage polarization in vivo can be manipulated
to alter disease outcome. Identifying the molecular mecha-
nisms that counteract or re-programme inappropriate
activation would not only improve understanding of
disease but also open up new avenues for more targeted
therapies. Recent studies, including our own, have estab-
lished the potential of suppressor of cytokine signalling
(SOCS) proteins to be such targets.6–9
SOCS proteins are a family of intracellular cytokine-
inducible proteins, consisting of eight members (CIS and
SOCS1–SOCS7).10 They negatively regulate Janus kinase
(JAK)/signal transducer and activator of transcription
(STAT) induced cytokine signalling through mechanisms
including their association with key phosphorylated tyro-
sine residues on JAK proteins and/or cytokine receptors
and degradation of signalling molecules through the
ubiquitin–proteasome pathway.10,11 SOCS1 and SOCS3
are rapidly induced in macrophages and have distinct
roles in shaping macrophage activation and controlling
immune and inflammatory responses.6,7 SOCS1 inhibits
macrophage responses to IFN-c and Toll-like receptor
(TLR) signalling and SOCS1-deficient mice succumb to
T-cell-mediated autoimmune inflammatory disease, char-
acterized by leucocyte infiltration and destruction of vital
organs.12,13 SOCS1, but not SOCS3, expression is strongly
up-regulated in an M2 polarizing environment in vitro
and in vivo, where it controls the activation phenotype.7
By contrast, SOCS3 attenuates gp130 signalling, limiting
IL-6-induced STAT1 gene expression and inhibiting IL-6-
induced STAT3 anti-inflammatory effects.14–16 In SOCS3/
 macrophages, IL-6 behaves more like the immunosup-
pressive cytokine IL-10 through prolonged STAT3 activa-
tion and suppression of lipopolysaccharide (LPS)
signalling.16 Consequently, mice lacking SOCS3 in myeloid
cells are resistant to endotoxic shock with reduced produc-
tion of pro-inflammatory cytokines.16 Moreover, studies
of rodent SOCS3-deficient macrophages show that
SOCS3 positively regulates TLR4 signaling,6,16–18 despite
earlier over-expression studies suggesting negative
regulation.19,20
We have previously established that macrophages infil-
trating inflamed glomeruli in experimental models are
rapidly polarized to express either SOCS1 or SOCS3 but
rarely both, with most exclusively expressing SOCS3.6 We
have also shown that SOCS3 is necessary to drive an M1-
polarized phenotype in vitro supporting a pro-inflamma-
tory role for this protein.6 However, two recent papers,
both using myeloid-specific SOCS3 knockout mice, have
shown conflicting results for the role of SOCS3 in M1
macrophage polarization in vivo, proposing that it either
promotes21 or inhibits22 pro-inflammatory responses.
These phenomena and mechanisms therefore need further
characterization. Moreover, the relevance of SOCS3 to the
inflammatory functions of human macrophages is
unknown. The present study was designed to address
these questions. Using robust models of inflammation, we
show that SOCS3 expression by macrophages within
injured tissue co-localizes with M1 macrophage activation
markers and that the proportion of these SOCS3-express-
ing macrophages correlates strongly with the severity of
immune-mediated injury. In line with this, we show that
SOCS3 controls M1-induced nuclear factor-jB (NF-jB)
activity, highlighting a new mechanism by which SOCS3
could promote M1 macrophage activation. The transla-
tional relevance of elevated SOCS3 in inflammation is
further illustrated by establishing its role in driving the
polarization and function of human M1 macrophages.
Materials and methods
Cells and reagents
Rat bone-marrow-derived macrophages (BMDMs) were
isolated by aspiration of the femur and tibia and suspended
in culture medium comprising Dulbecco’s modified Eagle’s
medium supplemented with 10% heat inactivated fetal calf
serum, 100 U/ml penicillin and 100 lg/ml streptomycin
with the addition of 20% L929-conditioned medium pro-
duced using a standard protocol.23 This yields a population
of > 95% macrophages after 7 days of culture. Blood was
donated by consenting healthy volunteers as approved by
the Ethics Review Board of the College of Life Science &
Medicine, University of Aberdeen. Human macrophages
and T cells were prepared from peripheral blood mononu-
clear cells separated by density gradient centrifugation
using a LymphoprepTM gradient medium (Axis-Shield,
Dundee, UK) according to the manufacturer’s instructions.
CD14+ monocytes and CD3+ T cells were isolated by posi-
tive selection from peripheral blood mononuclear cells
using antibody conjugated MicroBeads (Miltenyi Biotec,
Bisley, Surrey, UK). Monocytes were matured to macro-
phages by culture for 7 days in Dulbecco’s modified Eagle’s
medium supplemented with penicillin/streptomycin and
10% de-complemented sterile-filtered human AB+ serum.
Nephrotoxic serum was produced according to our stan-
dard protocol.23
Induction of peritonitis and nephrotoxic nephritis
Inbred male, Sprague Dawley rats (200–250 g) were bred
under standard conditions and maintained in all cases in
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accordance with United Kingdom Home Office regula-
tions. The animals were permitted access to food and
water ad libitum, and were maintained in a temperature-
and humidity-controlled room under a 12 hr day–night
cycle. Peritonitis was induced by intraperitoneal injection
of 1 ml 8% [weight/volume (wt/vol)] thioglycollate in
sterile saline followed 4 days later by intraperitoneal
injection of 3 mg/kg LPS from Escherichia coli (Sigma
Aldrich, Poole, UK) and adoptively transferred macro-
phages (6 9 106 to 10 9 106 cells per rat). Animals were
killed 4 hr after adoptive transfer of cells. Nephrotoxic
nephritis was induced by pre-immunization with subcuta-
neous injection of 1 mg of rabbit IgG (Sigma-Aldrich) in
Freund’s complete adjuvant and intravenous injection
1 week later with rabbit nephrotoxic serum. This results
in macrophage infiltration, acute glomerular injury, and
crescent formation. Rats were housed in metabolic cages
for 14 hr for urine collection. Urine albumin concentra-
tion was determined using rocket electrophoresis23 and
albuminuria was calculated as the total albumin excreted
over 24 hr. Sections of renal tissue fixed in methyl Car-
noy’s fixative were paraffin embedded, and 5-lm sections
were cut before routine staining with haematoxylin &
eosin.
Gene knockdown
Knockdown experiments were performed using pre-
designed and validated short interfering RNA (siRNA) for
SOCS3 (rat 192802, human s17191, Invitrogen, Life Tech-
nologies, Paisley, UK), SOCS1 (s16469, Invitrogen) or a
non-targeting siRNA sequence control (4390844, Invitro-
gen) containing at least four mismatches to any mouse,
human or rat gene. BMDM or human macrophages were
transfected using Lipofectamine RNAi Max (Invitrogen)
in serum-free medium according to the manufacturer’s
instructions. Three SOCS3 siRNA sequences were com-
pared for level of knockdown and the one giving most
efficient silencing was used in both cases. Mock transfec-
tion using Lipofectamine RNAi Max, but no siRNA and
no transfection controls, was included. In brief, at day 6
of differentiation, macrophages were plated in antibiotic-
free medium and transfected. After overnight incubation,
the medium was supplemented with antibiotics and cells
incubated at 37° for 48 hr before treatment. SOCS siRNA
transfection efficiency was 89  9% as determined by
counts for the number of macrophages containing fluor-
escently tagged siRNA (Invitrogen). Knockdown efficacy
was analysed by means of PCR and Western blotting. Cell
viability was not altered by transfection reagent alone
(mock transfection 989  12%) or by transfection with
siRNA (990  07%). Moreover, the siRNA transfection
procedure used did not stimulate IFN-c responses in
macrophages as assessed by analysis of expression of
IFN-c-responsive genes.
Adoptive cell transfer and conditioning in inflamed
peritoneum
Control siRNA or SOCS3 siRNA transfected BMDM
were labelled with the fluorescent dyes PKH2 or PKH26L
(Sigma Aldrich), injected into the activated peritoneum
and conditioned for 4 hr. Peritoneal exudate cells were
harvested from the animals by injecting 20 ml sterile
PBS through a small incision in the wall of the perito-
neal cavity. The abdomen was massaged and the con-
tents were transferred into a sterile polypropylene tube.
Adoptively transferred cells that had been conditioned in
the inflamed peritoneum were recovered by cell sorting
based on positivity in the FL1 channel in a Becton Dick-
inson BD FACSVantage SE Cytometer System, with
FACSDiVa High speed cell sorter (Becton Dickinson,
Oxford, UK).
Measurement of cytokine and NO levels and NF-jB
specific activation
Cell-sorted, control siRNA-treated or SOCS3 knockdown
BMDM recovered from the inflamed peritoneum were
plated at 2 9 105 cells in 200 µl per well in a 48-well
plate and cultured for 12 hr ex vivo for determination of
cytokines (IL-6 and IL-10 kits; BD Biosciences, Oxford,
UK) by cytometric bead arrays according to the manufac-
turer’s instructions. NO in the culture medium was
assessed by nitrite production using a Greiss reaction.23
In some experiments rat BMDM were pre-cultured in 24-
well plates with the phosphatidylinositol 3-kinase (PI3K)
inhibitor LY294002 (20 lM) or with vehicle control
(015% DMSO) for 40 min before the addition of IFN-c
(20 ng/ml) and LPS (100 ng/ml) for 10 hr to determine
IL-6 or NO concentrations as above. Concentrations of
IFN-c, IL-10 and IL-17 in human cell culture superna-
tants were determined using ELISA-matched antibody
pairs (BD Biosciences). Human IL-1b and IL-23 were
analysed using ELISA kits (eBiosciences, San Diego, CA).
Human IL-6, tumour necrosis factor-a (TNF-a) and IL-
12p70 were measured by cytometric bead array (BD Bio-
sciences) according to the manufacturer’s instructions.
NF-jB-specific activation in control siRNA- and SOCS3
siRNA-treated macrophages was measured using a Tran-
sAM ELISA-based kit (Active Motif, Carlsbad, CA) per-
formed on nuclear extracts of BMDM according to the
manufacturer’s protocol. Nuclear extracts were obtained
using a nuclear extraction kit (Active Motif) according to
the manufacturer’s instructions.
Immunohistochemistry
Total numbers of glomerular CD68+ macrophages were
detected in methyl Carnoy’s-fixed tissue by ED1 antibod-
ies (AbD Serotec, Kidlington, UK) and the Vectastain
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Elite ABC-Kit (Vector laboratories, Peterborough, UK)
with appropriate biotinylated secondary antibodies.
The peroxidase reaction product was visualized using
3,3′-diaminobenzidine (Sigma-Aldrich) as a chromogenic
substrate and H2O2 as co-substrate. The numbers of
CD68-positive glomerular macrophages that stained for
SOCS1 and/or SOCS3 were determined semi-quantita-
tively by co-localization studies using triple immunostain-
ing in the same methyl Carnoy’s fixed kidney sections as
follows. After quenching of endogenous peroxidase activ-
ity with 3% (vol/vol) H2O2 in methanol, tissues were
blocked with 1% (wt/vol) horse serum. To analyse the
numbers of SOCS1/SOCS3-positive glomerular macro-
phages, kidney sections were incubated with goat anti-rat
SOCS1 (1/200; Abcam, Cambridge, UK) and rabbit anti-
rat SOCS3 (1/500; Abcam), followed by the secondary
antibodies anti-rabbit TRITC and anti-goat FITC, respec-
tively. The sections were subsequently stained with ED1
antibody, peroxidase-conjugated secondary antibody and
3,3-diaminobenzidine (Sigma-Aldrich) as above. Negative
controls without primary antibody confirmed the specific-
ity of the reactions. Images were captured using an
Olympus 1 9 70 microscope. At least five glomeruli were
imaged per section for SOCS1/SOCS3-positive, CD68-
positive macrophages. The basal fluorescence (or chromo-
genic staining) was obtained, and a threshold was
automatically calculated, using sections without primary
antibody (negative control). Positive (SOCS1hi or SOC-
S3hi) macrophages were counted as those with a fluores-
cence intensity that exceeded the thresholds set for the
red and green channels; macrophages exhibiting no more
than background fluorescence were considered as SOCS1lo
or SOCS3lo, as described previously.6 The intensity of
staining was typically bimodal – those macrophages with
strong fluorescence and those with staining indistinguish-
able from background, as previously illustrated.6 Captured
images were merged to identify SOCS1/SOCS3-positive
macrophages and the proportions of SOCS1hi/lo SOCS3hi/
lo macrophages per glomerulus were determined.
Alternatively, to determine the proportions of SOCS1hi/lo
iNOShi/lo and SOCS3hi/lo iNOShi/lo macrophages, sections
were quenched and blocked as above and triple stained
with ED1 and rabbit anti-rat inducible nitric oxide syn-
thase (iNOS),24 followed by fluorescently labelled second-
ary antibodies and then goat anti-rat SOCS3 or SOCS1
(1 : 200; Abcam) with peroxidase-conjugated secondary
antibody and 3,3-diaminobenzidine. To minimize inter-
assay variation, all samples were processed in the same
batch. Images were captured and staining intensity thresh-
olds were set based on negative controls, without applica-
tion of the primary antibody as above. As with SOCS1/
SOCS3-positive macrophages, captured images were
merged to identify proportions of SOCS1hi/lo iNOShi/lo
and SOCS3hi/lo iNOShi/lo macrophages and expressed as
percentage of positive macrophages per glomerulus.
RNA isolation and RT-PCR
Macrophages recovered from the inflamed peritoneum
were pelleted and lysed and total RNA was prepared
using the Trizol extraction reagent (Invitrogen) followed
by RNA clean-up using an RNeasy mini kit (Qiagen,
Manchester, UK) according to the manufacturer’s instruc-
tions. A total of 5 lg from each sample was reverse tran-
scribed using the first-strand cDNA synthesis kit and
oligo(dT) primer as recommended by the manufacturer
(Invitrogen) in a 15-ll reaction volume. Relative quantifi-
cation of the genes of interest was measured as described
elsewhere.7 For each gene, the PCR was performed on 50,
100 and 200 ng of the cDNA using the following primers:
SOCS1 forward 5′-ATGGTAGCACGTAACCAG-3′
SOCS1 reverse 5′-CTCCAGCAGCTCGAAGAG-3′;
SOCS3 forward 5′-ACCAGCGCCACTTCTTCACA-3′
SOCS3 reverse 5′-GTGGAGCATCATACTGGTCC-3′;
iNOS forward 5′-TCTTGGTGAAAGCGGTGTT-3′
iNOS reverse 5′-TGTTGCGTTGGAAGTGTAGC-3′;
arginase I forward 5′-TATCTGCCAAGGACATCGTG-3′
arginase I reverse 5′-GTTCTGTTCGGTTTGCTGT-3′;
IL-10 forward 5′-CTCCACTGCCTTGCTTTTA-3′
IL-10 reverse 5′-CACTGCTATGTTGCCTGCTC-3′;
CD206 (mannose receptor) forward 5′-AACAAGAA
TGGTGGGCAGTC-3′
CD206 (mannose receptor) reverse 5′-AACTCCTCGTC
CGTCTGTC-3′;
GAPDH forward 5′-TGACATCAAGAAGGTGGTGA
AG-3′
GAPDH reverse 5′-TCTTACTCCTTGGAGGCCATGT-
3′.
Western blotting
Protein lysates were prepared from BMDM using lysis
buffer and 20 lg separated by SDS–PAGE and transferred
to Immobilon P membrane (Millipore, Watford, UK) for
Western blot analysis with specific primary antibodies
for SOCS3, IjB and p-IjB (Abcam), AKT and p-AKT
ser473 (Cell Signaling Technology, Herts, UK), p65 and
p-p65 ser536 (New England Biolabs, Herts, UK) and
b-actin (Sigma-Aldrich). Immunolabelled proteins were
detected by using appropriate horseradish peroxidase-
conjugated secondary antibodies, followed by visualization
with ECL (GE Healthcare, Buckinghamshire, UK). Bands
were normalized to b-actin.
T-cell proliferation assays
Human macrophages (1 9 105/well) were pre-treated with
or without LPS or IFN-c/LPS (20/500 ng/ml) for 7 hr and
pulsed with 5 lg/ml of a nominal antigen (keyhole limpet
haemocyanin) that elicits T-cell responses indirectly via
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macrophages. Macrophages were washed several times and
co-cultured with autologous CD4+ T cells (ratio 1 : 5).
After 8 days, T-cell proliferation was measured by [3H]
thymidine incorporation and cytokine secretion by ELISA.
Statistical analysis
Results are presented as mean  SD and differences
between groups of cells or animals were determined by
Student’s t-test or two-way analysis of variance followed
by a multiple range test (Tukey analysis). For experiments
with human macrophages a Wilcoxon rank sum test was
used to compare differences between groups. Correlations
between macrophage numbers and albuminuria were
assessed by linear regression analysis. Values of P < 005
were considered significant.
Results
SOCS3 expression in macrophages correlates with an
M1 phenotype and severity of nephritis
Most glomerular infiltrating macrophages in nephrotoxic
nephritis are strongly polarized to express abundant
SOCS3 without detectable SOCS1.6 There is in vitro evi-
dence that such macrophages are pro-inflammatory6 but
direct data from in vivo studies are lacking. Accordingly,
we double-stained SOCS3-positive macrophages within
inflamed glomeruli to determine whether they also
expressed the well-established rodent M1 macrophage
marker iNOS. Few macrophages were detected in normal
glomeruli (03  02 per glomerulus, mean  SD) and
these expressed little or no SOCS1, SOCS3 or iNOS
(Fig. 1a). Induction of nephrotoxic nephritis resulted in a
marked increase in glomerular macrophages that were
heterogeneous for SOCS expression but with SOCS1lo/
SOCS3hi macrophages predominating (Fig. 1b). Around
80% of glomerular macrophages strongly expressed iNOS
but this was largely restricted to those that were SOCS3hi
(696  124% total macrophages, 803  141% SOCS3-
expressing macrophages) supporting their proposed pro-
inflammatory nature (Fig. 1c,d). In contrast, the majority
of SOCS1hi-expressing macrophages (72  69%) did not
co-express iNOS (Fig. 1e,f), which is consistent with a
less inflammatory role.
Given the strong co-expression of SOCS3 and the M1
macrophage marker iNOS, we next determined if the
number of SOCS3-expressing macrophages within an
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Figure 1. The majority of suppressor of cyto-
kine signalling 3-high (SOCS3hi) expressing
macrophages strongly co-expressed the M1
marker inducible nitric oxide synthase (iNOS).
Triple immunostaining of a representative glo-
merulus from a non-diseased (a) and diseased
(c, e) animal after induction of nephrotoxic
nephritis. The number of CD68-positive mac-
rophages (green fluorescence) that were
SOCS3-positive (brown chromogenic stain)
and iNOS-positive (red fluorescence) (a, c), or
SOCS1-positive (brown chromogenic stain)
and iNOS-positive (red fluorescence) (e) are
shown. Original magnification 9 200. The
mean  SD percentage of macrophages
expressing, SOCS1 and SOCS3 (b); iNOS and
SOCS3 (d); or iNOS and SOCS1 (f) in glome-
ruli of rat kidney 3 days after induction of
nephrotoxic nephritis. The mean number of
total macrophages per nephritic glomerulus
was 186  82; n = 8 rats, at least five glome-
ruli per animal were analysed.
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inflamed environment was significantly associated with
the severity of inflammation. Injury in nephrotoxic
nephritis is macrophage-dependent and the intensity of
the macrophage infiltrate correlates with albuminuria,25
as we show again here (r2 = 0385, P = 0010; Fig. 2a).
Importantly, this correlation was attributable to the num-
bers of infiltrating SOCS3hi/SOCS1lo macrophages, which
correlated more strongly than total macrophages
(r2 = 0509, P = 0001; Fig. 2b), whereas the correlation
with SOCS3lo/SOCS1hi was not significant (P = 0120;
Fig. 2c). Collectively, the data demonstrate that despite
the heterogeneity of glomerular infiltrating macrophages,
SOCS3 expression identifies M1 activated cells whose
numbers correlate with levels of albuminuria, which
reflects the extent of damage to the glomerular filtration
barrier.
SOCS3 is essential for effective polarization of
pro-inflammatory macrophages in vivo
Using myeloid-specific knockout mice, SOCS3 has been
shown to either positively or negatively control M1 mac-
rophage polarization in vivo.21,22 To address these dis-
crepancies and further define the importance of SOCS3
in directing M1 activation in vivo, we used SOCS3 siR-
NA-silenced macrophages6 that were activated within an
inflamed rat peritoneum. The use of knockdown tech-
niques rather than gene-deleted macrophages avoided the
risk of compensatory effects in mice lacking SOCS3 and
modelled the effects of more subtle modulation of levels
rather than complete ablation.
Fluorescently labelled BMDM, transfected with SOCS3
or control siRNA, were injected into an inflamed rat peri-
toneum, recovered after 4 hr conditioning, purified by cell
sorting and analysed for mRNA expression or secretion of
inflammatory mediators. No significant difference between
kinetics of control siRNA- and SOCS3 siRNA-transfected
macrophages was observed in terms of the numbers of
injected cells remaining within the rat peritoneum after
transfer (control siRNA-transfected macrophages repre-
sented 98  49% total peritoneal cells; SOCS3 siRNA-
transfected macrophages represented 112  81% total
peritoneal cells after 4 hr). Macrophages conditioned in
the M1-activating environment again show strong expres-
sion of SOCS3 that was attenuated in SOCS3 siRNA-
transfected cells (Fig. 3a). Instead, there was a simulta-
neous and reciprocal up-regulation of SOCS1 (Fig. 3a)
that, in the absence of SOCS3, has been shown to be
associated with inhibition of pro-inflammatory responses,
M2 activation and reparative macrophages.7,11 The well-
recognized M2 activation marker mannose receptor, as
well as arginase I, which is induced by STAT3 and down-
regulates NO production in M1 activated cells,26 were
also significantly enhanced in SOCS3 knockdown macro-
phages activated in vivo (Fig. 3a,b), similar to the changes
observed with SOCS3 knockdown macrophages condi-
tioned more simply by IFN-c/LPS in vitro.6 In contrast to
in vitro experiments, the expression of IL-10 was signifi-
cantly increased. There was no change in mRNA expres-
sion of the M1 activation marker iNOS with SOCS3
knockdown. However, secretion of nitrite as a marker of
iNOS activity was significantly decreased by cells condi-
tioned in vivo before culture ex vivo (Fig. 3c), probably
due to an increase in arginase I activity. Furthermore, a
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Figure 2. Numbers of glomerular macrophages expressing suppres-
sor of cytokine signalling 3 (SOCS3) correlate strongly with severity
of injury in experimental nephritis. Triple immunostaining identified
SOCS1 and SOCS3 expressing CD68-positive macrophages. Macro-
phages exclusively expressing SOCS3 but not SOCS1 show a more
significant correlation with levels of albuminuria as a measure of
severity of disease (P = 0001) as compared with total macrophages
(P = 001), whereas, the number of macrophages exclusively express-
ing SOCS1 but not SOCS3 did not correlate with albuminuria
(P = 0120) suggesting they do not play a main role in driving dis-
ease severity.
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decrease in IL-6 production and, consistent with mRNA
analysis, significantly enhanced IL-10 secretion (Fig. 3c)
and up-regulation of SOCS1 at the protein level (Fig. 3d)
were observed. Therefore, consistent with our in vitro
polarization, SOCS3 is essential for effective M1 macro-
phage polarization in vivo and in its absence, macrophag-
es not only have an impaired ability to develop
pro-inflammatory properties when they enter an inflam-
matory environment but instead acquire anti-inflamma-
tory or homeostatic properties and some characteristics
of M2 macrophage subtypes (enhanced mannose receptor,
IL-10, SOCS1hi/SOCS3lo).
SOCS3 modulates NF-jB signalling in M1 activated
macrophages
NF-jB/p65 is central in driving M1 macrophage activa-
tion and expression of pro-inflammatory genes1 therefore
the importance of SOCS3 in directing M1 macrophage
characteristics through this pathway was determined. As
expected, NF-jB/p65 nuclear translocation and DNA
binding activity in nuclear extracts was up-regulated on
M1 activation in control siRNA-transfected macrophages
(Fig. 4a). This up-regulation was, however, significantly
less in SOCS3 siRNA-transfected cells, supporting a
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Figure 3. Suppressor of cytokine signalling 3 (SOCS3) knockdown macrophages injected into, and conditioned within, an in vivo inflamed envi-
ronment show decreased pro-inflammatory and enhanced anti-inflammatory characteristics. (a) PCR analysis showing SOCS3 knockdown macro-
phages (SOCS3) have enhanced mRNA for SOCS1, mannose receptor (MR), arginase I and interleukin-10 (IL-10) compared with control short
interfering RNA (siRNA) transfected cells (Con) after conditioning within an inflamed rat peritoneum in vivo. (b) Gene expression was quantified
using RT-PCR and normalized to the housekeeping gene. The results are shown as mean  SEM from n = 6 rats. (c) Production of macrophage
inflammatory mediators in supernatant of mock transfected, control siRNA transfected, or SOCS3 siRNA transfected macrophages isolated from
an in vivo conditioning environment and cultured for 12 hr before analysis for nitrite (NO), IL-10 and IL-6. Values represent mean concentra-
tion  SD, n = 6 animals/group (*P < 005). # Knockdown of SOCS3 in macrophages conditioned in an inflamed environment for 4 hr show a
reciprocal up-regulation of SOCS1 protein when analysed by immunoblotting with SOCS1, SOCS3 and b-actin antibodies.
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functional role for SOCS3 in NF-jB/p65 responses. NF-jB
nuclear activity is controlled upstream by the cytoplasmic
inhibitory protein IjBa so we repeated time-series experi-
ments and analysed IjBa degradation in cell lysates by
Western blotting. M1 activation resulted in obvious IjBa
degradation in control siRNA-treated cells, peaking at
30 min and showing evidence of re-synthesis at 60 min
(Fig. 4b,c). However, knockdown of SOCS3 substantially
inhibited M1 activation-induced IjBa degradation con-
firming that SOCS3 knockdown suppresses NF-jB activa-
tion upstream of DNA promoter binding. Furthermore,
IjB kinase (IKK) typically showed a decrease in activity
in the SOCS3 knockdown macrophages after M1 activa-
tion as assessed by Western blotting (see Supplementary
material, Fig. S1). There was, however, no detectable
interaction between SOCS3 and the IjB/p65 complex in
macrophages as assessed by immunoprecipitation (data
not included). Phosphorylation of p65 (Ser536), which
regulates the strength of transcriptional activity, was also
decreased in M1 activated SOCS3 knockdown cells over
the time course (Fig. 4b,c). Together, these results show
that SOCS3 can positively regulate early NF-jB signalling
in M1 activated macrophages.
Effects of SOCS3 knockdown on NF-jB activity is not
mediated via enhanced SOCS1
SOCS3 knockdown reciprocally up-regulates SOCS1
(Fig. 3). SOCS1 causes ubiquitination and proteosomal
degradation of IL-1 receptor-associated kinase 1, the
adaptor protein TIRAP/Mal as well as nuclear p65, to
abrogate NF-jB activation.10,27–29 To determine whether
up-regulated SOCS1 was responsible for the SOCS3-
silencing mediated effects, SOCS1 and SOCS3 were
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Figure 4. Nuclear factor-rB (NF-rB)/p65 activity is decreased in suppressor of cytokine signalling 3 (SOCS3) knocked down M1 activated mac-
rophages. Bone marrow-derived macrophages (BMDM) were transfected with control short interfering RNA (siRNA) or SOCS3 siRNA. Forty-
eight hours following transfection, cells were stimulated without or with lipopolysaccharide (LPS). (a) Nuclear protein extracts were prepared
and assessed for NF-rB/p65 activity by a DNA binding ELISA as described in the Materials and methods. Values show mean percentage SD of
NF-jB/p65 activity in cells transfected with SOCS3 siRNA relative to LPS-stimulated cells transfected with control siRNA; n = 6. (b) Immunoblot
analysis of SOCS3, IjB and phospho-p65 in lysates of BMDM transfected with control siRNA or SOCS3 siRNA treated with interferon-c (IFN-
c)/LPS for 0, 15, 30 and 60 min with b-actin as a loading control. SOCS3 knockdown decreased SOCS3 protein expression, decreased the rate of
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blots (c). *P < 005.
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knocked down simultaneously and NF-jB/p65-activity
was determined. Knockdown of SOCS3 at the protein
level was efficient (68  5%) and resulted in the expected
reciprocal up-regulation of SOCS1 protein by at least
twofold in M1 activated cells (Fig. 5a). Double knock-
down silenced SOCS1 or SOCS3 as efficiently as in single
knockdown cells but critically, did not restore NF-jB/p65
activity to control levels (Fig. 5b). The decrease in NF-
jB-activity with SOCS3 knockdown was therefore not
simply due to up-regulated SOCS1 expression.
SOCS3 knockdown results in an increase in PI3K
(pAKT) activity on M1 activation
Effects of SOCS3 silencing on the down-regulation of
TLR4 signalling have been proposed to occur indirectly
through STAT3, which can inhibit NF-jB and could
account for the decrease in NF-jB activity in our
knockdown macrophages.16 However, the change in NF-
jB activity in our SOCS3 silenced macrophages is an
early response (30 min post stimulation) and likely to
occur before the LPS-induced up-regulation in STAT3
activity that is typically found at least 1 hr after stimu-
lation.16,22,30 Induction of PI3K-AKT signalling by TLRs
is an important early feedback inhibitory mechanism
that limits NF-jB activation and inflammatory cytokine
production.31,32 SOCS3 binds phosphorylated receptors
and inhibits downstream PI3K-AKT activity in other
systems,33–38 therefore we next determined whether
silencing SOCS3 also affected this pathway in M1 acti-
vated macrophages. On M1 activation, SOCS3 knock-
down significantly increased p-AKT levels (serine 473),
a surrogate marker of PI3K activation (Fig. 6a,b) sup-
porting the view that SOCS3 also regulates this pathway
in macrophages. To determine whether this provided a
potential mechanism by which SOCS3 controls macro-
phage NF-jB signalling, effects were determined after
pre-incubation with the well-known PI3K inhibitor,
LY294002. As previously shown, SOCS3 knockdown
resulted in a significant decrease in nuclear NF-jB/p65
activity in M1 activated macrophages; LY294002 pre-
incubation abrogated this decrease (Fig. 6c). Moreover,
pre-incubation with LY294002 prevented the inhibition
of nitrite production (34  6%, P < 005) by M1 acti-
vated SOCS3-silenced cells compared with cells trans-
fected with control siRNA (Fig. 6d). Similar results were
observed when IL-6 production was measured (Fig. 6e)
indicating that the SOCS3-induced inhibition of PI3K is
upstream of its effects on NF-jB activation. Taken
together, these results suggest that, as well as modulat-
ing STAT3 to control the NF-jB activity, SOCS3 could
limit PI3K/AKT activation to ensure effective pro-
inflammatory M1 responses.
SOCS3 silencing alters cytokine production and
activation of adaptive responses by human
M1-activated macrophages
Given the disparities in macrophage activation and func-
tions between species,37 it was important to address the
potential for SOCS3 in driving the polarization of human
macrophages, and, critically, functional consequences of
SOCS3 silencing in these cells. As with the rodent cells,
SOCS3 protein is strongly induced in M1-activated
human macrophages (see Supplementary material,
Fig. S2a). Moreover, SOCS3 knockdown results in a
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Figure 5. Knocking down suppressor of cytokine signalling 1
(SOCS1) and SOCS3 simultaneously does not restore the SOCS3-
mediated decrease in nuclear factor-rB (NF-rB)/p65 activity in M1
activated macrophages. Bone marrow-derived macrophage (BMDM)
were transfected with control short interfering RNA (siRNA), SOCS3
siRNA or SOCS1 siRNA (Invitrogen) in a single or combined man-
ner. (a) Forty-eight hours following transfection, cells were incubated
with interferon-c (IFN-c)/lipopolysaccharide (LPS) for 30 min.
SOCS1, SOCS3 and b-actin protein expression was detected by Wes-
tern blotting showing successful knockdown at the protein level. The
intensity of SOCS1 and SOCS3 bands on the blots were determined
by densitometry and normalised to b-actin; n = 3. (b) Nuclear NF-
jB/p65 DNA binding activity was measured using a TransAM NF-
jB kit and demonstrated simultaneous SOCS1&3 knockdown does
not restore nuclear NF-jB activity. Data shows the NF-jB/p65 activ-
ity in cells transfected with SOCS1 and/or SOCS3 siRNA relative to
cells transfected with control siRNA, *P < 002, n = 5.
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reciprocal up-regulation of SOCS1 and a substantial
increase in STAT3 but not STAT1 activity upon LPS
stimulation (Fig. S2b–d). Next we defined the effects of
SOCS3 knockdown on the inflammatory cytokine profile
of LPS and LPS/IFN-c-stimulated human macrophages by
analysing the supernatants collected from transfected cells.
SOCS3 knockdown significantly decreased the secretion
levels of macrophage-derived IL-1b, IL-6, IL-12p70
and IL-23 in IFN-c/LPS-activated SOCS3 knockdown
macrophages and IL-6 and IL-12p70 in LPS-activated
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Figure 6. Suppressor of cytokine signalling 3 (SOCS3) knockdown results in an increase in phosphatidylinositol 3-kinase (PI3K) (pAKT) activity
on M1 activation and inhibition of PI3K activity reverses the SOCS3 knockdown inhibitory effects on nuclear factor-jB (NF-jB). (a) Bone mar-
row-derived macrophages (BMDM) were transfected with control short interfering RNA (siRNA) or SOCS3 siRNA. Forty-eight hours following
transfection, cells were stimulated without or with interferon-c (IFN-c)/lipopolysaccharide (LPS) and PI3K activity assessed by Western blotting
for pAKT with loading control b-actin. Figure shows expression of proteins as determined by an immunoblot, representative of three individual
experiments. (b) Normalized densitometric analysis of scanned bands in arbitary units (A. U.); n = 3; *P < 005. (c) Incubation of SOCS3 knock-
down macrophages for 1 hr with the PI3K inhibitor LY294002 (20 lM) before M1 activation for 30 min abrogated the significant decrease in
NF-jB/p65 activity in SOCS3 siRNA-transfected macrophages; DMSO (015%) served as a vehicle control. The inhibition of nitrite (d) and IL-6
(e) production in the culture supernatant of M1 activated, SOCS3 silenced cells compared with control siRNA-transfected cells was also pre-
vented after pre-incubation with LY294002 for 40 min before M1 activation for an additional period of 10 hr. As LY294002 can interfere with
basal NF-jB activity, values for control siRNA transfected cells with or without LY294002 were set to 100% for (c) to (e). n = 4; *P < 005.
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macrophages (Fig. 7a). In contrast, concentrations of M1-
induced TNF-a, IL-10 and transforming growth factor b
(TGF-b; data not included) were not significantly altered.
This demonstrates for the first time that SOCS3 selec-
tively regulates the extent of macrophage pro-inflamma-
tory potential in activated human cells.
M1 macrophages function as antigen-presenting cells
and can drive T-cell responses. As SOCS3 knockdown
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Figure 7. Suppressor of cytokine signalling 3 (SOCS3) knockdown macrophages show distinct cytokine secretion profile following differential
activation. (a) Macrophages were transfected with control or SOCS3-specific short interfering RNA (siRNA). Macrophages were differentially acti-
vated with 100 ng/ml lipopolysaccharide (LPS) alone or in combination with 20 ng/ml IFN-c and cells were loaded with nominal antigen (key-
hole limpet haemocyanin). Supernatants of macrophage cultures were collected 24 hr after activation and analysed by cytometric bead array
[interleukin-6 (IL-6), IL-12, tumour necrosis factor-a (TNF-a), IL-10] and ELISA (IL-1b, IL-23); n = 6. (b) Autologous T cells were added to
macrophages treated as above and cells were co-cultured for 8 days after which T-cell proliferation ([3H]thymidine incorporation) and T-cell
cytokine secretion levels (ELISA) were measured. The plots show the mean  SEM. Statistical significance was based on Wilcoxon matched-pairs
signed rank test. n = 8; * P < 005.
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resulted in a decrease in the T helper type 17 (Th17)
polarizing cytokines IL-1b, IL-6, IL-23 and the Th1 polar-
izing cytokine IL-12 by activated macrophages, we tested
if this was functionally important and would alter their
ability to induce responses to antigens by autologous T
cells. Macrophages transduced with SOCS3 siRNA or
control siRNA were loaded with a nominal antigen, (key-
hole limpet antigen) and activated with LPS or IFN-
c/LPS to induce T-cell polarizing cytokines. This method
avoids the non-specific effects that can result with simul-
taneous anti-CD3 activation, or synthetic T-cell polarizing
conditions using anti-cytokine antibodies. As shown in
Fig. 7b, activation in the presence of antigen resulted in a
marked increase in T-cell proliferation and T-cell cyto-
kine production. Knockdown of SOCS3 attenuated both
the capacity to stimulate T-cell proliferation and the
secretion of cytokines in the supernatant of macrophage-
activated T-cell cultures. Specifically, there was a decrease
in the secretion of IFN-c and IL-17, important signature
cytokines associated with pro-inflammatory Th1 and
Th17, respectively, while levels of IL-10 from activated T-
cell cultures (associated with Th2 and T regulatory cells)
were maintained. Taken together these results show that
SOCS3 is also essential in regulating the pro-inflamma-
tory and functional properties of human macrophages
and its knockdown results in an overall dampening of
innate and downstream adaptive immune responses.
Discussion
We show for the first time that SOCS3 expression identi-
fies a population of macrophages in vivo that express M1
markers and correlates specifically with the intensity of
tissue injury. The enhanced SOCS3, as well as modulating
STAT activity, restrains signalling through the PI3K/Akt
pathway, which in turn augments NF-jB activity to drive
efficient expression of pro-inflammatory mediators. Con-
sequently, in the absence of SOCS3, macrophages default
to a less inflammatory state on entering a pro-inflamma-
tory milieu. These effects are not confined to rodents and
we show the translational relevance and functional signifi-
cance of SOCS3 in driving M1 activation in human
monocyte-derived macrophages, where it fine tunes the
production of inflammatory cytokines and downstream T
helper cell priming, especially that of IL-17-producing
effector cells. Hence, our results demonstrate that SOCS3
is not simply a feedback inhibitor of cytokine responses
but selectively controls multiple pathways to regulate
tightly M1 macrophage activation and tailor an appropri-
ate inflammatory response.
An important aspect of our studies was that the major-
ity of M1 macrophages activated in an in vivo pro-inflam-
matory conditioning environment show strong up-
regulation of SOCS3 expression and without this, these
macrophages have a reduced ability to develop pro-
inflammatory features. This strongly contrasts with mac-
rophages infiltrating an in vivo M2-activating environ-
ment, where macrophages with enhanced SOCS1 but not
SOCS3 are prominent and SOCS1 is critical in the acquisi-
tion of M2 characteristics.7 Collectively, these studies high-
light the heterogeneity of macrophages in vivo and the
disparate effects of SOCS proteins in controlling effective
subset activation. Our up-regulation of SOCS3 by macro-
phages activated in vivo (Fig. 1) and their strong associa-
tion with tissue injury (Fig. 2) is remarkably similar to the
phenotype and role of SOCS3-expressing macrophages
induced by IFN-c/LPS in vitro,6 despite the much more
complex conditioning environment. A key difference,
however, is the strong induction of IL-10 gene expression
and secretion by SOCS3-deficient macrophages activated
within the inflamed peritoneum. Interleukin-10 is up-reg-
ulated by TLR agonists to prevent overshooting of TLR-
mediated pro-inflammatory responses and in vivo SOCS3
appears to actively repress this feedback to maintain suffi-
ciently the natural cytotoxicity of M1-polarized macro-
phages. NF-jB p50/p50 homodimers have been shown to
promote LPS-induced IL-10 expression and drive macro-
phages to an immunosuppressive M2-like phenotype, dur-
ing resolution of inflammation.38,39 Whether SOCS3 exerts
inhibitory effects on IL-10 expression in vivo via inhibition
of this mechanism needs to be addressed further.
Initial studies using over-expression systems suggested
that SOCS3, like SOCS1, was a negative regulator of
TLR4 signalling and synthetically high SOCS3 expression
resulted in a less pro-inflammatory phenotype.19,20 How-
ever, more recent studies, including our own, have con-
cluded that SOCS3 positively regulates TLR4 and
inflammatory responses.6,17,18,40 Genetically modified
mice, selectively lacking SOCS3 in myeloid cells, are resis-
tant to LPS-induced acute inflammation16,21 and polymi-
crobial sepsis.21 The same mice exhibited resistance to the
tumour transplantation model because of reduced
tumour-promoting cytokines such as TNF-a and IL-6
and enhanced production of anti-tumorigenic chemokine
MCP2/CCL8 with anti-inflammatory effects relating to
increased phosphoSTAT3.41 An opposing study in LysM-
Cre-SOCS3 fl/fl mice, however, found exacerbated inflam-
mation in response to septic shock and, in spite of
elevated STAT3 activity,22 suggested a role for SOCS3 in
limiting M1 activation. The reason for this discrepancy is
unclear but may relate to differences in purity and dose
of LPS used in each study, the difference in control group
mice (wild-type control versus SOCS3 floxed transgenic
control) and the genes and time-points analysed after
macrophage activation. We clearly show here that SOCS3
knockdown macrophages conditioned in an LPS-activated
peritoneum also show a reduced ability to become polar-
ized to an M1 subtype in vivo, consistent with an essential
role for SOCS3 in driving pro-inflammatory responses in
macrophages.
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Previously, SOCS has been shown to modulate LPS-
induced IL-6-, IL-10- and IFN-c-dependent STAT path-
ways,16–18 possibly accounting for some of the changes in
inflammatory properties in knockdown macrophages in
our study. SOCS3 has also been shown to promote TLR4
responses in macrophages in vitro, by feedback inhibiting
TGF-b1/Smad3 signalling that down-regulates LPS-
induced cytokine production.18 Here we propose an alter-
native and novel mechanism whereby SOCS3 promotes
LPS-induced inflammatory responses, through enhancing
early NF-jB signalling and subsequently secretion of pro-
inflammatory mediators. We show that silencing of
SOCS3 resulted in a decrease in M1 macrophage-induced
IjB degradation, phospho-p65 levels as well as down-
stream nuclear p65-NF-jB activity; it has been proposed
that SOCS3 exerts positive effects on the NF-jB promoter
activity in a RelA-dependent manner.42 Interestingly, our
SOCS3 knockdown macrophages show a strikingly similar
phenotype to those transduced with an IjB super repres-
sor that decreases NF-jB nuclear activity, attenuates pro-
inflammatory responses, enhances IL-10 and, when adop-
tively transferred, decreases the severity of experimental
nephritis.25
Silencing of SOCS3 resulted in a strong up-regulation
of human and rodent macrophage SOCS1 that inhibits
NF-jB activity at several levels.10,27,29 Notably, the inhibi-
tion of NF-jB signalling in SOCS3 knockdown macro-
phages was not, however, due to the reciprocally induced
up-regulation of SOCS1. Nor is it likely to be solely due
to hyper-activation of STAT3, which represses LPS-
induced NF-jB activity.43 In contrast to IL-6, LPS
induces STAT3 activity with delayed kinetics18 (> 1 hr)
and in our study the decrease in LPS-induced NF-jB
activity in SOCS3-deficient macrophages was observed
within 30 min post activation. However, we show an
early increase in PI3K-AKT activity in M1-activated
SOCS3 knockdown macrophages. This is consistent with
the proposed inhibitory role of SOCS3 for PI3K in other
systems, where it competes with SH2-containing adaptor
molecules that recruit PI3K for activation, or inhibits
JAK2 activity and subsequent PI3K phosphorylation.33–36
PI3K negatively regulates early TLR-induced pro-inflam-
matory cytokine production, enhances IL-10 and sup-
presses NF-jB cascades in response to LPS in
monocytes.31,32,44 PI3K-induced AKT activity also inhibits
glycogen synthase kinase (GSK)-3b, which facilitates
NF-jB activation via the IKKb-IjBa-p65 signalling
pathway.45 A notable feature of our studies was that inhi-
bition of PI3K reversed the repressive effects of SOCS3
knockdown on NF-jB activity, IL-6 and nitrite produc-
tion in M1 activated macrophages. This supports the view
that up-regulated SOCS3 restricts PI3K to augment NF-
jB activity and promote an efficient M1 activation
response. Although the exact mechanism by which SOCS3
controls M1-induced NF-jB activity is still unclear, we
propose that there is an important contribution from this
pathway, in addition to effects on STAT3 and TGF-b1/
Smad3 activity.16,18
Our results in rodent macrophages proposed SOCS3 as
a target molecule to redirect macrophage functions as a
potential treatment of inflammatory disease and therefore
we translated our findings to human macrophages. Stud-
ies on the mechanistic role of SOCS3 in human macro-
phage activation are limited, but its expression is elevated
in several acute inflammatory disorders.8,9 As with rodent
cells, the production of pro-inflammatory cytokines (IL-
1b, IL-6, IL-23, IL-12) was significantly decreased by
SOCS3 silencing in human monocyte-derived macrophag-
es in our studies but with specificity in their regulation
and no significant change in TNF-a levels. This is in
keeping with previous studies in human macrophages
where SOCS3 over-expression had no effect on LPS-
induced TNF-a mRNA levels46 and demonstrating SOCS3
regulates expression of pro-inflammatory mediators in a
gene-specific manner.
A key attribute of macrophages at sites of inflammation
is that they can present antigen and secrete cytokines to
prime and control the magnitude of T-cell responses.47 A
striking feature of our results is the reduced potential of
SOCS3 silenced macrophages to drive T effector cell dif-
ferentiation, especially that of Th17. This reduced ability
may be partially explained by a decrease in expression of
co-stimulatory molecules in SOCS3-silenced cells.6 How-
ever, we speculate that the change in cytokine polarizing
environment plays a much more significant role. All three
Th17 polarizing cytokines (IL-1b, IL-6 and IL-23) show
reduced production with SOCS3 knockdown, with IL-1b
showing the most significant decrease. In line with this,
our unpublished work and that of others show that IL-1b
is key to driving Th17 polarization in human macrophag-
es.48 The addition of these polarizing cytokines to cultures,
rather than reliance on their inherent production by mac-
rophages, may explain the apparently paradoxical report
that macrophages from LysMCre-SOCS3fl/fl mice exhibited
an enhanced Th1 and Th17 polarizing ability.22 Studies in
mouse SOCS3–/– dendritic cells showed a similar reduced
potential to drive T effector cell responses and a tolero-
genic phenotype and this was due to their enhanced TGF-
b production and selective expansion of Foxp3-positive
regulatory T cells.49 However, we found no evidence of
enhanced TGF-b production or regulatory T-cell polariza-
tion by SOCS3 knockdown macrophages in our study.
Taken together, it is clear that the regulation of intracellu-
lar signalling pathways by SOCS3 in innate cells is critical
for the decision of adaptive responses such as T-cell fates.
The depletion of macrophage SOCS3 in a clinical situation
would therefore be predicted to dampen both pro-inflam-
matory innate and adaptive immune responses.
In conclusion, macrophage functions depend on their
polarizing microenvironment and controlling their
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responses is a key factor for the outcome of both inflamma-
tion and autoimmune disease. Our data identify an addi-
tional and novel role for SOCS3 in fine-tuning macrophage
polarization, via its effects on intracellular signalling
pathways including PI3K and NF-jB that direct M1 mac-
rophage function. Therefore modulation of macrophage-
specific SOCS3 expression could provide new opportunities
for therapeutic manipulation of immune responses.
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Figure S1. Phosphorylated IjB kinase (p-IKK) levels
are decreased in suppressor of cytokine signalling 3
(SOCS3) knocked down M1 activated macrophages. Mac-
rophages were transfected with control short interfering
RNA (siRNA) or SOCS3 siRNA. 48 hr following transfec-
tion, cells were stimulated without or with lipopolysac-
charide (LPS) for 0, 15 and 30 min and p-IKK and IKK
levels were assessed by Western blotting. Densitometric
analysis was performed on scanned bands and results pre-
sented as the ratio of p-IKK to b-actin in arbitrary units
(a.u.). Figure is representative of five individual experi-
ments.
Figure S2. Human monocyte derived macrophages
were activated with 100 ng/ml lipopolysaccharide (LPS)
for 4 hr or left untreated (non-stimulated). Total macro-
phage protein was isolated and expression of protein and
loading control b-actin detected by Western blot and
normalized by densitometric analysis of scanned bands in
arbitrary units (n = 4). (a) Suppressor of cytokine signal-
ling 3 (SOCS3) expression increases upon LPS stimula-
tion in human monocyte derived macrophages. (b)
SOCS3 knockdown (S3) in human monocyte derived
macrophages decreases SOCS protein expression as com-
pared with control (con) short interfering RNA (siRNA)
transfected cells. (c) Knockdown of SOCS3 (S3) in
human monocyte derived macrophages increases phos-
phorylated signal transducer and activator of transcription
3 (pSTAT3), but not pSTAT1, levels and (d) increases
SOCS1 expression after LPS stimulation.
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